 |
|
Study looks at new bladder cancer therapy for patients unresponsive to standard treatment
February 27, 2008As many as half of patients with superficial bladder cancer do not respond to the standard first-line chemotherapy placed into the bladder, according to current multi-center outcomes data. When this happens, typically, their only option is surgical removal of the bladder. Now, researchers at the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center are investigating an FDA-approved metastatic breast-cancer drug called Abraxane® that may prove a safe and effective alternative to surgery for these patients.
Bladder cancer is the fourth leading cause of cancer in men and the ninth leading cause of cancer in women in the United States. In a given year, more than 60,000 new cases are diagnosed, and 13,000 will die from the disease.
"When the standard treatment does not work, currently the only option is surgical removal of the bladder -- something that, for all patients, is unappealing, and for some sicker patients is not even possible. With this study, we hope to find an effective second line medical option for these patients," says Dr. James McKiernan, director of urologic oncology at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center, and vice chairman of the Department of Urology and assistant professor of urology at Columbia University College of Physicians and Surgeons.
The Phase I/II study will follow 18 patients for six weeks to assess dosage safety, followed by a second group of 19 patients who will be followed for six weeks to measure the effectiveness of the therapy.
The study is open to patients with recurrent bladder cancer that has not responded to standard therapy -- BCG (bacillus Calmette-Guerin) treatment.
In 2006, Dr. McKiernan, together with departmental chair Dr. Mitchell C Benson, led a phase I study of the drug Taxotere, also used to treat breast cancer, on a similar patient population, finding the drug to be safe with 12 of 18 patients responding (results were published in the July 1, 2006, Journal of Clinical Oncology). Since then, a favorable percentage of patients have survived with intact bladders.
Abraxane, he believes, will show similar or better results. "Abraxane has an analogous structure to Taxotere, but has the advantage of being more soluble due to its solvent-free formulation allowing for administration at higher concentrations," says Dr. McKiernan. "In one study of Abraxane for metastatic breast cancer, the drug successfully shrank tumors and had few side effects."
New York- Presbyterian Hospital/Columbia University Medical Center
The Phase I/II study will follow 18 patients for six weeks to assess dosage safety, followed by a second group of 19 patients who will be followed for six weeks to measure the effectiveness of the therapy.
The study is open to patients with recurrent bladder cancer that has not responded to standard therapy -- BCG (bacillus Calmette-Guerin) treatment.
In 2006, Dr. McKiernan, together with departmental chair Dr. Mitchell C Benson, led a phase I study of the drug Taxotere, also used to treat breast cancer, on a similar patient population, finding the drug to be safe with 12 of 18 patients responding (results were published in the July 1, 2006, Journal of Clinical Oncology). Since then, a favorable percentage of patients have survived with intact bladders.
Abraxane, he believes, will show similar or better results. "Abraxane has an analogous structure to Taxotere, but has the advantage of being more soluble due to its solvent-free formulation allowing for administration at higher concentrations," says Dr. McKiernan. "In one study of Abraxane for metastatic breast cancer, the drug successfully shrank tumors and had few side effects."
New York- Presbyterian Hospital/Columbia University Medical Center
Bladder Cancer Current Events and Bladder Cancer News RSSPrediction model superior to traditional criteria in bladder treatment decision
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy.
Hopkins scientists find cells responsible for bladder cancer's spread
Johns Hopkins scientists have tracked down a powerful set of cells in bladder tumors that seem to be primarily responsible for the cancer's growth and spread using a technique that takes advantage of similarities between tumor and organ growth.
Variation in prostate stem cell antigen gene raises bladder cancer risk
Researchers have pinpointed a specific gene variation that causes increased risk of urinary bladder cancer, according to a scientific team led by The University of Texas M. D. Anderson Cancer Center.
UT Southwestern researchers investigate high-risk populations for bladder-cancer screenings
A new study by UT Southwestern Medical Center researchers sheds light on the challenges involved in identifying which high-risk population would benefit most from bladder-cancer screening.
DKK-3 and WIF-1: Proteins related to liver cancer development?
Liver cancer is one of the most fatal human malignancies and the third most frequent cause of tumor-related death, about half a million people globally each year.
Certain ecologic factors associated with greater risk of bladder cancer
Persons drinking well water (as opposed to public supply) may be at an increased risk of bladder cancer, according to new research from the University of Alabama at Birmingham. Researchers will present data about the relationship between bladder cancer and certain ecologic factors including water source and UV radiation levels at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence
Making tumors inside the bladder fluoresce red under blue light allows physicians to more easily find and remove them, substantially reducing the rate at which these cancers come back, says a Mayo Clinic physician who is presenting results of a large, multicenter international clinical trial.
Genetic Variants Predict Recurrence of Bladder Cancer, Patient Survival
Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle invasive bladder cancer (NMIBC) who are treated with mainstream therapy.
More intense bladder cancer treatment does not improve survival, U-M study finds
Despite enduring more invasive tests and medical procedures, patients who were treated aggressively for early stage bladder cancer had no better survival than patients who were treated less aggressively.
New Discovery Raises Doubts About Use of Certain Targeted Therapies in Bladder Cancer
Researchers at the University of Virginia Health System have found that one of the genes commonly thought to promote the growth and spread of some types of cancers is in fact beneficial in bladder cancer - a major discovery that could significantly alter the way bladder cancers are treated in the future.
More Bladder Cancer Current Events and Bladder Cancer News Articles
 |
Bladder Cancer: A Resource Guide for Patients and Their Families by Gary Dunetz (Author) If you, a loved one or friend has been diagnosed with bladder cancer, learning the basics is of utmost importance. It is essential to understand the nature of the disease, the work up and variety of treatments which are available. This book is comprehensive yet user friendly. It is written in a question and answer format in conversational tone. The physician author is a clinical urologist who has guided many individuals with bladder cancer through diagnosis and the various forms of treatment. This resource should enable those with bladder cancer and their family and friends to face this challenge with reason. After reading this book, you will be able to make an informed decision as you collaborate with your physician to regain your health. This book is written to allow the reader to have... |
 |
100 Questions & Answers About Bladder Cancer by Pamela Ellsworth (Author), Brett Carswell (Author) Approximately 62,000 people are diagnosed with bladder cancer each year, making bladder cancer the fourth most common type of cancer in men and the eighth most common type in women. Whether you're a newly diagnosed bladder cancer patient, a survivor, or a friend or relative of either, this book offers help. The only book to provide both the doctor's and patient's views, 100 Questions & Answers About Bladder Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, coping strategies, sources of support, and much more. Written by two prominent urologists, with "insider" advice from actual patients, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease. |
 |
Bladder Cancer (Cleveland Clinic Guide) by M D Raghavan (Author), Kathleen Tuthill (Author) Cancer that arises in the bladder is one of the most common malignancies in industrialized societies and yet is not well understood in the community at large. Bladder Cancer: A Cleveland Clinic Guide provides simple, non-medical explanations of this disease for people who have to deal with this illness, either as patients or as those who care for these patients. |
 |
The Guide to Living with Bladder Cancer by Dr. Mark P. Schoenberg MD FACS (Author) Johns Hopkins Univ., Baltimore, MD. Text for families and patients facing this disease. Discusses the structure and function of the urinary tract, an overview of bladder cancer and risk factors, symptoms, surgery, life after surgery, principles of chemotherapy, tests and diagnosis, and major surgical procedures. Hardcover, soft not available |
 |
Bladder Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Bladder Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Bladder Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Bladder Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Fight Against Bladder Cancer T-shirt Large White by Shop Zeus |
 |
Fight Against Bladder Cancer Mug by Design a Product LLC Text on mug: Fight Against Bladder Cancer * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
 |
Olympian Labs Prosplex For Men by Olympian Labs The prostate is a doughnut shaped gland located behind the pubic bone and below the bladder in males. It surrounds the neck of the bladder and the urethra, a small tubular structure that drains urine from the bladder to the penis. The prostate gland is a common site of Malfunction of mind or bodys in the male genitourinary system. As men age, their prostate gland often enlarges. This condition is referred to as Benign Prostate Hypertrophy or BPH. Over 50% of American men will develop an enlarged prostate in their lifetime. Dietary supplementation of nutrients essential for prostate health have been shown to be effective in the relief of BPH. |
 |
Treatment and Management of Bladder Cancer (with CD) by Seth P. Lerner (Editor), Mark Schoenberg (Editor), Cora Sternberg (Editor) Bladder cancer is an international public health problem affecting millions of people in both developed and underdeveloped nations. This major urologic malignancy was one of the first cancers to be linked to occupational and environmental exposure to carcinogens. Bladder cancer is the 5th most common cancer of American men and the 8th most common cancer of American women. Sixty thousand new cases of the disease are diagnosed each year in the US alone; disease prevalence is high in western nations due to the predominance of the chronic relapsing form of cancer that occurs in these countries (USA prevalence estimated to be 600,000; NCI-SEER database). This single fact makes bladder cancer one of the most expensive cancers to treat. Treatment and Management of Bladder Cancer, drawing on... |
 |
The Cleveland Clinic Guide to Bladder Cancer (Cleveland Clinic Guides) by Derek Raghavan (Author) Expert medical advice from the Chairman of the Cleveland Clinic Taussig Cancer Institute. Every year, 60,000 people are diagnosed with bladder cancer. If found early, bladder cancer is highly treatable,but it does have a high rate of recurrence. Staying informed is key for those facing a diagnosis as well as for those living with the disease. Dr. Derek Raghavan is one of the country’s leading experts in this field and, as the Chairman of the Cleveland Clinic Taussig Cancer Institute, he has access to the latest research and studies. In The Cleveland Clinic Guide to Bladder Cancer, he provides all of the essential information needed to understand and manage the challenges of bladder cancer. |
| © 2009 BrightSurf.com |